InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces First Quarter 2021 Financial and Business Results
May 11, 2021 16:47 ET | Interpace Biosciences, Inc.
 ● Q1 Revenue of $9.8 Million is Company’s Highest as Combined Molecular Diagnostics and Pharma Services Business  ● Q2 Revenue Expected to Exceed $11 million  ● On Track to Exceed Full Year 2021...
InterpaceBiosciences_New Logo.png
Interpace Biosciences to Explore Strategic Alternatives for Maximizing Shareholder Value
April 22, 2021 08:00 ET | Interpace Biosciences, Inc.
Parsippany, NJ, April 22, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today issued the following statement. Interpace continues to make...
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois
February 25, 2021 16:31 ET | Interpace Biosciences, Inc.
In-network status for ThyGeNEXT® and ThyraMIR® with State’s Largest Payer PARSIPPANY, NJ, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or “the Company”), today...
Interpace Biosciences Announces Acceptance for Trading on the OTCQX
February 24, 2021 17:54 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, today...